The atrial appendage occluder market size is projected to be valued at USD 983.5 million in 2023 and is expected to rise to USD 8193.0 million by 2033. The sales of atrial appendage occluders are projected to expand at a significant CAGR of 23.6% during the forecast period.
Atrial appendage occluders are medical devices used to close off the left atrial appendage, a small pouch in the heart that is prone to blood clot formation in patients with atrial fibrillation.
The market for atrial appendage occluders is driven by several factors. Firstly, there has been a significant increase in the prevalence of atrial fibrillation globally, primarily due to aging populations and the growing burden of risk factors such as obesity, diabetes, and hypertension. As a result, there is a high demand for effective treatment options to manage this condition and reduce the associated risks.
There is a growing preference for minimally invasive procedures among patients and healthcare providers. Atrial appendage occluders offer a less invasive alternative to open-heart surgery for the closure of the left atrial appendage.
Advancements in technology and product innovation have enhanced the safety and efficacy of atrial appendage occluders. Further, manufacturers are developing next-generation devices with improved design features, such as better sealing mechanisms, ease of implantation, and enhanced long-term outcomes.
Looking ahead, the atrial appendage occluder market is expected to continue its growth trajectory. Moreover, the increasing prevalence of atrial fibrillation, the demand for minimally invasive treatments, and ongoing advancements in device technology are estimated to drive the market’s expansion.
Key Takeaways:
- The endocardial segment is expected to dominate the global atrial appendage occluder market, accounting for a market share of 87.20%. This segment is preferred due to its safety and effectiveness, supported by positive results from clinical studies. It is anticipated to have a low complication rate compared to the epicardial segment, driving its growth.
- The epicardial segment is forecasted to hold a market share of 15%.
- The hospital segment is projected to be the most dominant contributing to 63.20% of the global atrial appendage occluder market. The increasing number of hospitals and improved infrastructure are driving the demand for these devices.
- North America is expected to dominate the atrial appendage occluder market, with a market share of 39.8%. The region’s large geriatric population and the high number of stroke-related deaths contribute to the increased demand for atrial appendage occluders in this market.
- The demand for atrial appendage occluders is likely to rise with over 6 million people in Europe living with arrhythmia, and the number is expected to double in the next 50 years The European race has a high incidence of atrial fibrillation, and sedentary lifestyles in developed nations contribute to cardiovascular problems. Europe held a market share of 27.3% in the atrial occluder market in 2022.
Rising Demand for Market Data: Our Full Report Offers Deep Insights and Trend Analysis!
Recent Developments:
- In June 2022, AtriCure, Inc., a pioneer in surgical treatments and therapies for atrial fibrillation, left atrial appendage (LAA) control, and post-operative pain management, announced that the first patient in the HEAL-ISTTM study has been treated (NCT 05280093). Drs. Mark LaMeir and Carlo de Asmundis treated the first patient at University Hospital Brussels.
- In May 2022, B. Braun Interventional Systems Inc. secured an exclusive distribution deal with Occlutech (BIS). With the backing of the worldwide Occlutech team, BIS is going to begin US commercialization initiatives for Occlutech’s Flex II ASD Occluder.
Key Companies Profiled:
Appriva Medical Inc.; Boston Scientific; Abbott; SentreHEART Inc; pfm medical ag.; Occlutech; W. L. Gore & Associates; Coherex Medical, Inc.; Cardia, Inc.; AtriCure, Inc.
Key Segments Covered in the Atrial Appendage Occluder Market Report:
By Type of indication:
- Non-valvular Atrial Fibrillation
The Procedure of Positioning of the Device:
- Endocardial
- Epicardial
By End-user:
- Hospitals
- Clinics
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific Excluding Japan (APEJ)
- Japan
- The Middle East & Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube